Yang Maoquan, Liu Yan, Zheng Shuangshuang, Geng Peizhen, He Tianhao, Lu Linan, Feng Yikuan, Jiang Qiqi
School of Clinical Medicine, Shandong Second Medical University, Weifang 261042, Shandong, China.
Department of Gastroenterology, Weifang People’s Hospital, The First Affiliated Hospital of Shandong Second Medical University, Kuiwen, Weifang 261000, Shandong, China.
Aging (Albany NY). 2024 Mar 27;16(7):6068-6097. doi: 10.18632/aging.205689.
Programmed death-1 and its ligand-1 (PD-1/PD-L1), immune checkpoints proteins, play a crucial role in anti-tumor responses. A large number of studies have evaluated the relationships of PD-1/PD-L1 polymorphisms with risk of cancer, but evidence for the associations remains inconsistent. Therefore, we performed a meta-analysis to examine the associations between PD-1/PD-L1 single nucleotide polymorphisms (SNPs) and cancer predisposition. Results showed that PD-1.3 and PD-L1 rs17718883 were significantly correlated with overall cancer risk. PD-1.5 was prominently linked with cervical cancer (CC), non-small cell lung cancer (NSCLC), TC (thyroid cancer), brain tumor, AML (acute myelocytic leukemia) and UCC (urothelial cell carcinoma) risk, PD-1.9 with breast cancer (BC), AML, esophageal cancer (EC) and ovarian cancer (OC) risk, and PD-1.3 with colorectal cancer (CRC) and BCC (basal cell carcinoma) risk. PD-1.1 polymorphism slightly elevated BC and OC susceptibility, whereas the rs4143815 variant notably decreased the risk of gastric cancer (GC), hepatocellular carcinoma (HCC) and OC, but increased the risk of BC. PD-1.6 was closely linked with AML risk, PD-L1 rs2890658 with NSCLC, HCC and BC risk, rs17718883 with HCC and GC risk, rs10815225 with GC risk, and rs2297136 with NSCLC and HCC risk. Interestingly, the rs7421861, rs10815225, and rs10815225 markedly reduced cancer susceptibility among Asians. The rs7421861 polymrophism decreased cancer risk among Caucasians, rather than the rs10815225 elevated cancer risk. Our results supported that PD-1 and PD-L1 SNPs were dramatically correlated with cancer risk.
程序性死亡蛋白 1 及其配体 1（PD-1/PD-L1）作为免疫检查点蛋白，在抗肿瘤反应中发挥着关键作用。大量研究评估了 PD-1/PD-L1 基因多态性与癌症风险的关系，但相关关联的证据仍不一致。因此，我们进行了一项荟萃分析，以研究 PD-1/PD-L1 单核苷酸多态性（SNP）与癌症易感性之间的关联。结果显示，PD-1.3 和 PD-L1 rs17718883 与总体癌症风险显著相关。PD-1.5 与宫颈癌（CC）、非小细胞肺癌（NSCLC）、甲状腺癌（TC）、脑肿瘤、急性髓细胞白血病（AML）和尿路上皮癌（UCC）风险显著相关，PD-1.9 与乳腺癌（BC）、AML、食管癌（EC）和卵巢癌（OC）风险相关，PD-1.3 与结直肠癌（CRC）和基底细胞癌（BCC）风险相关。PD-1.1 多态性略微增加了 BC 和 OC 的易感性，而 rs4143815 变体显著降低了胃癌（GC）、肝细胞癌（HCC）和 OC 的风险，但增加了 BC 的风险。PD-1.6 与 AML 风险密切相关，PD-L1 rs2890658 与 NSCLC、HCC 和 BC 风险相关，rs17718883 与 HCC 和 GC 风险相关，rs10815225 与 GC 风险相关，rs2297136 与 NSCLC 和 HCC 风险相关。有趣的是，rs7421861、rs10815225 和 rs10815225 显著降低了亚洲人的癌症易感性。rs7421861 多态性降低了白种人的癌症风险，而不是 rs10815225 增加了癌症风险。我们的结果支持 PD-1 和 PD-L1 SNP 与癌症风险显著相关。
Zotero 插件
